NDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AN-DTPA is a technetium Tc-99m pentetate kit, a radiopharmaceutical diagnostic agent approved in 1976 for nuclear medicine imaging. It is used as a trace agent to visualize organ function and perfusion in diagnostic imaging procedures. The product works by binding to tissues and organs of interest, allowing gamma camera detection for functional assessment.
LOE Approaching
This legacy diagnostic product faces approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team consolidation and focus on operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AN-DTPA offers limited career growth opportunities given the zero linked job postings and approaching loss of exclusivity. Roles focus on operational efficiency, market maintenance, and compliance rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on AN-DTPA at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.